Nyrada, Inc. · ASX:NYR
Nyrada — BioShares Biotech Summit 2025
12 slides from Nyrada's conference presentation, Aug 6, 2025
Slide 1: BioShares Biotech Summit Presentation
6 August 2025 Sydney, Australia BioShares Biotech Summit Presentation Nyrada Inc (ASX:NYR), a clinical stage drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel inhibitors, provides the enclosed investor presentation to be delivered
Slide 2: Investor Presentation
For personal use only Investor Presentation BioShares Presentation - August 2025 James Bonnar – CEO Improving Lives, Offering Hope ASX:NYR Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.
Slide 3: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should not be Such forward-looking statements do not guarantee of future performance and involve known considered as an offer or invitation to subscribe for, or purchase any securities in NYR,
Slide 4: Nyrada Overview
Nyrada Overview › Small molecule drug discovery and development For personal use only company › Focus on calcium channel dysfunction › Lead drug candidate – Xolatryp (NYR-BI03). › Potent 3rd generation TRPC 3, 6 and 7 channel inhibitor › Novel and well-understood mechanism of action › Solid scientif
Slide 5: TRPC Channel Inhibition - Origins
TRPC Channel Inhibition - Origins Lutz Birnbaumer Birnbaumer’s Mice For personal use only 4
Slide 6: TRPC Channels - Cardioprotection
TRPC Channels - Cardioprotection For personal use only Cell Type TRPC Activation Effect Xolatryp Inhibition Effect Cardiomyocytes Calcium overload → cell death Prevents damage, preserves function and contractility Endothelial Impaired repair → poor blood flow Enhances vessel repair, reduces inflamma
Slide 7: Ischemia Reperfusion – Last Cardiac Frontier
Ischemia Reperfusion – Last Cardiac Frontier For personal use only PCI (Balloon Angioplasty): • First procedure in 1977, stents in 1994, • Standard of care for STEMI by early 2000s 6
Slide 8: Preclinical Study
Preclinical Study 1 Key Preclinical Results: Xolatryp showed strong For personal use only efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion (IR) injury • 86% Cardioprotection • 43% increase in left ventricular ejection fraction • 50% increase in fractional shorte
Slide 9: Preclinical Study
Preclinical Study 2 Key Preclinical Results: For personal use only Xolatryp showed strong efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion injury when administered as a short-duration intravenous infusion • 42% Cardioprotection • 88% decrease in arrhythmias at 1
Slide 10: Poised for Value Inflection
Poised for Value Inflection For personal use only Source: Karst Peak Rx - www.kp-rx.com 9
Slide 11: Conclusion
Conclusion › Nyrada – the company For personal use only › Pioneering TRPC channel inhibition therapies › AU$2.93 million cash position at end June 2025 › AU$8.25 million capital raised in August 2025 › Xolatryp – the lead drug asset › Solid scientific foundations and well understood mechanism of act
Slide 12: For personal use only
For personal use only @nyrada_inc @nyrada_inc info@nyrada.com www.nyrada.com 11